MX374223B - Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. - Google Patents

Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.

Info

Publication number
MX374223B
MX374223B MX2015012666A MX2015012666A MX374223B MX 374223 B MX374223 B MX 374223B MX 2015012666 A MX2015012666 A MX 2015012666A MX 2015012666 A MX2015012666 A MX 2015012666A MX 374223 B MX374223 B MX 374223B
Authority
MX
Mexico
Prior art keywords
rosuvastatin calcium
valsartan
manufacturing
effects
preparation
Prior art date
Application number
MX2015012666A
Other languages
English (en)
Other versions
MX2015012666A (es
Inventor
Geun Tae Kim
Jeong Uk Song
Ki Kon Lee
Sun Ll Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2015012666A publication Critical patent/MX2015012666A/es
Publication of MX374223B publication Critical patent/MX374223B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica que incluye valsartan y rosuvastatina cálcica como ingredientes activos, y a un método de fabricación para la misma. La composición farmacéutica que incluye valsartan y rosuvastatina cálcica de acuerdo con la presente invención puede aliviar los efectos secundarios de las preparaciones individuales existentes y simultáneamente mejorar el acatamiento de los pacientes que tienen una enfermedad cardiovascular, una enfermedad hiperlipidémica y una enfermedad compleja de las mismas, e incrementa los efectos de tratamiento y prevención, y en particular, obtiene efectos sinergísticos en el tratamiento de la hiperlipidemia, y aumenta la velocidad de disolución de valsartan y rosuvastatina cálcica y los efectos de tratamiento al granular valsartan y mezclar la rosuvastatina cálcica.
MX2015012666A 2013-03-12 2014-03-11 Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. MX374223B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130026146 2013-03-12
PCT/KR2014/002008 WO2014142521A1 (ko) 2013-03-12 2014-03-11 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법

Publications (2)

Publication Number Publication Date
MX2015012666A MX2015012666A (es) 2016-02-16
MX374223B true MX374223B (es) 2025-03-05

Family

ID=51537085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012666A MX374223B (es) 2013-03-12 2014-03-11 Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.

Country Status (10)

Country Link
US (1) US20160045497A1 (es)
EP (1) EP2977048A4 (es)
JP (1) JP2016514125A (es)
KR (2) KR20140111982A (es)
CN (1) CN105163734A (es)
AU (1) AU2014230304B2 (es)
CA (1) CA2903961A1 (es)
MX (1) MX374223B (es)
RU (1) RU2663460C2 (es)
WO (1) WO2014142521A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160095826A (ko) * 2015-02-04 2016-08-12 제이더블유중외제약 주식회사 피타바스타틴 또는 이의 약학적으로 허용 가능한 염 및 발사르탄 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
PL3320903T3 (pl) * 2015-07-08 2021-12-06 Hk Inno.N Corporation Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1353727A2 (en) * 2000-12-01 2003-10-22 Novartis AG Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CN102973942B (zh) * 2006-10-30 2015-08-12 韩诺生物制约株式会社 包含血管紧张素II受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
RU2450823C2 (ru) * 2009-10-26 2012-05-20 Общество С Ограниченной Ответственностью "Исследовательский Центр "Комкон" Средство для лечения связанных со стрессовыми условиями заболеваний и расстройств у человека и животных, а также способ лечения и/или профилактики с использованием этого средства
UY33772A (es) * 2010-12-09 2012-07-31 Lg Life Sciences Ltd Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma.

Also Published As

Publication number Publication date
AU2014230304B2 (en) 2018-07-05
AU2014230304A8 (en) 2015-10-15
CA2903961A1 (en) 2014-09-18
KR20190108090A (ko) 2019-09-23
KR102306005B1 (ko) 2021-09-28
EP2977048A1 (en) 2016-01-27
US20160045497A1 (en) 2016-02-18
RU2015143218A (ru) 2017-04-17
KR20140111982A (ko) 2014-09-22
RU2663460C2 (ru) 2018-08-06
EP2977048A4 (en) 2017-04-26
CN105163734A (zh) 2015-12-16
WO2014142521A1 (ko) 2014-09-18
JP2016514125A (ja) 2016-05-19
MX2015012666A (es) 2016-02-16
AU2014230304A1 (en) 2015-10-01
BR112015022103A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
MX340985B (es) Compuestos de n-heteroarilo.
EA201591618A1 (ru) Замещенные имидазопиридазины
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
MY174729A (en) Pharmaceutical combination drug
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
MX374223B (es) Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
IN2013MU03428A (es)
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
IN2014DN10683A (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LG CHEM, LTD.

FG Grant or registration